Former Klick Health Senior Vice President of Activation Strategy, Silvia De Carvalho, moves to front AXON’s clinical studies practice globally as clinical studies lead. She brings almost two decades of healthcare marketing expertise.
De Carvalho started her career working with the clinical development teams at Sanofi to identify optimal protocols and product viability in the diabetes landscape.
“Silvia is a wonderful addition to the AXON team, not only bringing a strong strategic mind to our client business, but also a high level of ambition for what we can achieve,” said Ralph Sutton, international managing partner of AXON, and its parent company AVENIR GLOBAL.
De Carvalho will help shape how AXON will support patients, caregivers, healthcare professionals, and broader stakeholders navigate the healthcare industry.
“Building on a great foundation, I am excited to continue our growth journey alongside our clients. A first key area of focus for us will be an expansion on our digital engagement services and how we can help clients optimally recruit and engage patients and healthcare professionals within digital and decentralized trials, but also effectively embrace adaptive trial design. The second area of focus will be helping clients to reach diverse patient populations to reflect the communities who may benefit from their medicines," said De Carvalho.
AXON HIRES SILVIA DE CARVALHO AS NEW CLINICAL STUDIES LEAD. (2023, July 17). AXON.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.